CagriSema — the research designation for the combination of cagrilintide (an amylin analogue) with semaglutide — represents one of the more scientifically well-grounded combination approaches in current metabolic research. Unlike some peptide combinations that are studied based on theoretical synergy, the GLP-1/amylin combination has a mechanistic foundation that is reasonably well understood.